PerkinElmer has entered into an agreement to acquire Nexcelom Bioscience for $260 million. The transaction is expected to close during the second quarter of 2021.   Nexcelom is a global provider of automated cell counting instruments, image cytometry workstations, assays and a variety of cell reagents, consumables, and fit-for-purpose cell counting method selection and development instructions that follow ISO Cell Counting Standards and aid in the development of cell and gene and immuno-oncology...